NCT07521384 (MuSE-INSIGHT) is a clinical trial in Traumatic Brain Injury, sponsored by Healing Hope International.

Who is sponsoring NCT07521384?

NCT07521384 is sponsored by Healing Hope International.

What condition does NCT07521384 study?

NCT07521384 studies Traumatic Brain Injury, Cerebral Palsy, Hypoxic Ischemic Encephalopathy, Neurologic Disorders, MS (Multiple Sclerosis), Alzheimer Dementia (AD), Parkinson Disease (PD), Stroke, Autism.

Is NCT07521384 still recruiting?

NCT07521384 is currently enrolling by invitation. Last updated 9 April 2026.

Last reviewed 2026-04-09 · How we verify

NCT07521384: MuSE-INSIGHT

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Real World Outcomes of Intranasal MuSE Exosomes and Stem Cells in Neurological Regenerative Therapy

ENROLLING BY INVITATION Last updated 9 April 2026

What this trial tests

trial in Traumatic Brain Injury in 36 participants. Enrolling by invitation.

Timeline

1 June 2026

Primary endpoint
1 January 2028

30 January 2029

Quick facts

Lead sponsor	Healing Hope International
Status	ENROLLING BY INVITATION
Study type	OBSERVATIONAL
Enrollment	36
Start date	1 June 2026
Primary completion	1 January 2028
Estimated completion	30 January 2029
Sites	1 location across Mexico

Conditions studied

Traumatic Brain Injury — all drugs for Traumatic Brain Injury →
Cerebral Palsy — all drugs for Cerebral Palsy →
Hypoxic Ischemic Encephalopathy — all drugs for Hypoxic Ischemic Encephalopathy →
Neurologic Disorders — all drugs for Neurologic Disorders →

Sponsor

Healing Hope International — full company profile →

Who can join

Adults 4 to 80, any sex, with Traumatic Brain Injury or Cerebral Palsy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This prospective observational study collects real world data on participants receiving regenerative therapies administered internationally and delivered intranasally via the Kurve Therapeutics ViaNase device. The study does not assign treatment. Participants are enrolled after receiving, or electing to receive, therapy as part of routine clinical care outside the study. Participants are observed in one of three cohorts based on the therapy received: MuSE cell derived exosomes, MuSE stem cells, or combination therapy. The objective is to evaluate safety, tolerability, and changes in inflammatory biomarkers and clinical outcomes over time in a real world setting. The study also evaluates changes in inflammatory biomarkers, including serum tumor necrosis factor alpha (TNF-α), to better understand the biological effects of these therapies.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Traumatic Brain Injury

Currently open trials in the same condition.

NCT07176936 — Improving Speech in Noise Using Noninvasive Stimulation · NA · recruiting
NCT07473505 — Integrative Bilateral Cervical Sympathetic Blocks for Trauma-Related Symptoms in Special Operations Veterans: A Prospect · recruiting
NCT07455136 — A Study to Develop a Blood-based Test for Aiding the Diagnosis/Prognosis of Traumatic Brain Injury in Adults and for Mon · recruiting
NCT07404761 — Safety and Effectiveness of Spatial StimelMD (SSMD) in Subjects With Upper Limb Neuromotor Impairments · NA · recruiting
NCT07230002 — Effects of Moderate/Severe Traumatic Brain Injury in the Subacute or Chronic Phase on Locomotor Strategies Involved in N · NA · recruiting

Other Healing Hope International trials

Trials by the same sponsor.

NCT07521371 — Intranasal Insulin for Autism Spectrum Disorder in Children and Young Adults Aged 4 to 21 Years · enrolling by invitation
NCT07511660 — Intra Ovarian Muse Cell Injection for Perimenopause Symptom Relief and Ovarian Function Restoration (MUSE-OVARY) · enrolling by invitation
NCT07493096 — Intensive Multimodal Neurorehabilitation Targeting Neuroplasticity in Pediatric Neurodevelopmental and Chromosomal Disor · recruiting
NCT07264166 — Intranasal AAV9-PHP.eB Gene Therapy in Cerebral Palsy (CP) & Hypoxic Ischemic Encephalopathy (HIE) · enrolling by invitation

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07521384 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Healing Hope International
Last refreshed: 9 April 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07521384.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing